Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05132582
Title A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Acronym HER2CLIMB-05
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Seagen Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | NLD | ITA | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS


No variant requirements are available.